We employed the c‐Src activity level (1 minus p‐c‐Src (Y530)/c‐Src ratio) as a tumor marker for the first time and found that it was not only significantly higher in chemoresistant patients but also positively correlated with a poor prognosis for survival. This evidence concerns the gene SRC and neoplasm.